en Anglais
af Afrikaanssq Albanaisam Amharicar Arabehy Arménienaz Azerbaïdjanaiseu Basquebe Biélorussebn Bengalibs Bosnienbg Bulgareca Catalanceb Cebuanony Chichewazh-CN Chinois (simplifié)zh-TW Chinois (traditionnel)co Corsehr Croatecs Tchèqueda Danoisnl Néerlandaisen Anglaiseo Esperantoet Estonientl Philippinfi En finnoisfr Françaisfy Frisongl Galicienka Géorgiende Allemandel Grecgu Gujaratiht Créole haïtienha Hausahaw Hawaïenneiw En hébreuhi Hindihmn Hmonghu Hongroisis Islandaisig Igboid Indonésienga Irlandaisit Italienja Japonaisjw Javanaiskn Kannadakk Kazakhkm Khmerko Coréenku Kurde (Kurmanji)ky Kirghizelo Laola Latinlv Lettonlt En lituanienlb En luxembourgeoismk Macédonienmg Malgachems Malaisml Malayalammt Maltaismi Maorimr Marathimn Mongolmy Myanmar (Birmanie)ne Népalaisno Norvégienps Pachtounefa Persanpl Polonaispt Portugaispa Punjabiro En roumainru Russesm Samoangd Gaélique écossaissr Serbest Sesothosn Shonasd Sindhisi Sinhalask Slovaquesl Slovèneso Somalienes Espagnolsu Soudanaissw Swahilisv Suédoistg Tadjikta Tamilte Teluguth Thaitr Turcuk Ukrainienur Urduuz Ouzbékistanvi Vietnamiency Galloisxh Xhosayi Yiddishyo Yorubazu Zulu

Blog de l'avocat

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR!! May this year increase your hope and happiness! Let’s go forward together to Defeat MSA forever! We thank you for your continued support! www.msacanada.ca/donate-to-us/ #defeatmsa #kickmsa

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MSA BLOGUE 

Blog des aidants

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR FROM ALL OF US!

HAPPY NEW YEAR!! May this year increase your hope and happiness! Let’s go forward together to Defeat MSA forever! We thank you for your continued support! www.msacanada.ca/donate-to-us/ #defeatmsa #kickmsa

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Blog des chercheurs

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MODAG Collaboration Update – MSA Drug

MODAG Collaboration Update – MSA Drug

Congratulations to MODAG! On behalf of MSA/AMS patients around the world, we are thankful for your efforts! 💜. https://www.tevapharm.com/news-and-media/latest-news/teva-and-modag-announce-licensing-collaboration-for-neurodegenerative-disease-drug-candidate/

Patient’s Blog

You May Also Like…

Français du Canada